University of Miami

1. GlaxoSmithKline, LLC. $18,673,625 544 payments
2. Amgen Inc. $14,574,609 23 payments
3. Pfizer Inc. $9,219,593 525 payments
4. Biogen, Inc. $8,035,283 44 payments
5. Novartis Pharmaceuticals Corporation $7,818,241 76 payments
6. Merck Sharp & Dohme Corporation $5,267,829 104 payments
7. Gilead Sciences, Inc. $4,460,926 481 payments
8. AbbVie, Inc. $4,082,801 286 payments
9. Deciphera Pharmaceuticals Inc. $3,927,777 569 payments
10. Regeneron Pharmaceuticals, Inc. $3,740,630 316 payments

1. 0000000000000000000000000000000000000000000000000000000000000000220780 $15,856,227 1 payment
2. A Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Standard of Care to Determine MRD Negativity in Patients with Newly-Diagnosed Multiple Myeloma ADVANCE $7,591,173 2 payments
3. A Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Standard of Care to Determine MRD Negativity in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE) $6,772,150 5 payments
4. A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension $3,816,429 5 payments
5. Ribociclib Standard Endocrine Therapy in Patients With HR Her2 Early BC at High Amp Intermediate Risk for Recurrence $3,375,314 13 payments
6. A Phase 1B2 Open Label Umbrella Study of Elranatamab Pf06863135 A Bcell Maturation Antigen Bcma Cd3 Bispecific Antibody in Combination With Other Anticancer Treatments in Participants With Multiple Myeloma $2,514,479 89 payments
7. Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma $2,380,986 64 payments
8. Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab $2,347,168 197 payments
9. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $1,755,265 3 payments
10. A Master Protocol for the Multi-Cohort, Phase 1/2 Study of Dcc-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies $1,489,489 78 payments

1. Other $868,707 192 payments
2. Patient care $423,280 44 payments
3. Overhead $12,231 1 payment
4. Non-patient care $7,381 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.